Alternating Mitomycin C and Bacillus Calmette-Guerin Instillation Therapy for Carcinoma in Situ of the Bladder

Abstract

No AccessJournal of UrologyClinical Urology: Original Article1 Dec 1995Alternating Mitomycin C and Bacillus Calmette-Guerin Instillation Therapy for Carcinoma in Situ of the Bladder Erkki Rintala, Kari Jauhiainen, Pertti Rajala, Mirja Ruutu, Eero Kaasinen, Olof Alfthan, and The Finnbladder Group Erkki RintalaErkki Rintala More articles by this author , Kari JauhiainenKari Jauhiainen More articles by this author , Pertti RajalaPertti Rajala More articles by this author , Mirja RuutuMirja Ruutu More articles by this author , Eero KaasinenEero Kaasinen More articles by this author , Olof AlfthanOlof Alfthan More articles by this author , and The Finnbladder Group More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)66691-6AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Our aim was to prove if alternating chemotherapeutic and immunotherapeutic instillations improved efficacy and reduced toxicity in patients with carcinoma in situ of the bladder. Materials and Methods: Of 68 carcinoma in situ patients randomly treated with instillations 40 received mitomycin C and 28 received mitomycin C and Pasteur bacillus Calmette-Guerin (BCG) in alternating courses. Mean followup was 33 months. Results: The complete response rates with mitomycin C and mitomycin C/BCG were 45 percent and 71 percent at 3 months, 59 percent and 82 percent at 12 months, and 47 percent and 74 percent at 24 months, respectively (p = 0.041). The disease-free interval showed the superiority of alternating therapy (p = 0.043). Recurrence rates during the instillation period were 1.834 with mitomycin C and 0.922 with mitomycin C/BCG (p = 0.013). No remarkable side effects developed in the alternating group. Conclusions: Therapy of carcinoma in situ with alternating mitomycin C and BCG is more effective than mitomycin C alone. Compared to BCG monotherapy only few side effects occur. References 1 : Mitomycin instillation to prevent recurrence of superficial bladder carcinoma. Results of a controlled, prospective study in 58 patients.. Eur. Urol.1983; 9: 84. Google Scholar 2 : Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder.. J. Urol.1986; 135: 265. Abstract, Google Scholar 3 : Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer.. J. Urol.1989; 142: 719. Abstract, Google Scholar 4 : A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder.. New Engl. J. Med.1991; 325: 1205. Google Scholar 5 : Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guerin) in superficial bladder cancer.. Eur. Urol.1991; 20: 19. Google Scholar 6 : Intravesical instillation of Adriamycin.. A model for standardization of the chemotherapy. Eur. Urol.1980; 6: 218. Google Scholar 7 : Intravesical cytostatics: pH-dependence of antitumour activity.. Urol. Res.1985; 13: 19. Google Scholar 8 : Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients.. J. Urol.1990; 144: 68. Abstract, Google Scholar 9 : Treatment of superficial bladder cancer with intravesical mitomycin C: analysis of immediate and long-term response in 70 patients.. J. Urol.1985; 134: 1107. Abstract, Google Scholar 10 : Effect of mitomycin C and doxorubicin instillation on carcinoma in situ of the urinary bladder.. A Finnish multicenter study. Eur. Urol.1986; 12: 32. Google Scholar 11 : Intravesical mitomycin C for carcinoma in situ of the urinary bladder.. Scand. J. Urol. Nephrol.1990; 24: 35. Google Scholar 12 : Immunotherapy of superficial bladder cancer with BCG.. World J. Urol.1986; 3: 209. Google Scholar 13 : The influence of Tice strain BCG treatment in patients with transitional cell carcinoma in situ.. Prog. Clin. Biol. Res.1989; 310: 193. Google Scholar 14 : Long-term effect of intravesical bacillus Calmette-Guerin (BCG) Tice strain on flat carcinoma in situ of the bladder.. Prog. Clin. Biol. Res.1989; 310: 171. Google Scholar 15 : Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer.. J. Clin. Oncol.1988; 6: 1450. Google Scholar 16 : Rationale for intensive intravesical chemotherapy. Progress and Controversies in Oncological Urology. New York: Alan R. Liss1984: 287. Google Scholar 17 : Doxorubicin plus mitomycin C regimen in the prophylactic treatment of superficial bladder tumors.. Cancer1988; 62: 1055. Google Scholar 18 : Cytostatic effect of different strains of Bacillus Calmette-Guerin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon-alfa.. Urol. Res.1992; 20: 215. Google Scholar 19 : Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma.. J. Urol.1982; 128: 27. Abstract, Google Scholar 20 : A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer.. J. Clin. Oncol.1987; 5: 441. Google Scholar 21 : Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.. J. Urol.1992; 147: 596. Abstract, Google Scholar 22 : Carcinoma in situ.. Urol. Clin. N. Amer.1992; 19: 499. Google Scholar Department of Urology, Helsinki University Central Hospital, Helsinki, Finland.© 1995 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited bySYLVESTER R, van der MEIJDEN A, WITJES J and KURTH K (2018) BACILLUS CALMETTE-GUERIN VERSUS CHEMOTHERAPY FOR THE INTRAVESICAL TREATMENT OF PATIENTS WITH CARCINOMA IN SITU OF THE BLADDER: A META-ANALYSIS OF THE PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALSJournal of Urology, VOL. 174, NO. 1, (86-91), Online publication date: 1-Jul-2005.SYLVESTER R, van der MEIJDEN A and LAMM D (2018) Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical TrialsJournal of Urology, VOL. 168, NO. 5, (1964-1970), Online publication date: 1-Nov-2002.KAASINEN E, RINTALA E, PERE A, KALLIO J, PUOLAKKA V, LIUKKONEN T and TUHKANEN K (2018) WEEKLY MITOMYCIN C FOLLOWED BY MONTHLY BACILLUS CALMETTE-GUERIN OR ALTERNATING MONTHLY INTERFERON-α2B AND BACILLUS CALMETTE-GUERIN FOR PROPHYLAXIS OF RECURRENT PAPILLARY SUPERFICIAL BLADDER CARCINOMAJournal of Urology, VOL. 164, NO. 1, (47-52), Online publication date: 1-Jul-2000.ALI-EL-DEIN B, NABEEH A, ISMAIL E and GHONEIM M (2018) SEQUENTIAL BACILLUS CALMETTE-GUERIN AND EPIRUBICIN VERSUS BACILLUS CALMETTE-GUERIN ALONE FOR SUPERFICIAL BLADDER TUMORS: A RANDOMIZED PROSPECTIVE STUDYJournal of Urology, VOL. 162, NO. 2, (339-342), Online publication date: 1-Aug-1999.WITJES J, CARIS C, MUNGAN N, DEBRUYNE F and WITJES W (2018) RESULTS OF A RANDOMIZED PHASE III TRIAL OF SEQUENTIAL INTRAVESICAL THERAPY WITH MITOMYCIN C AND BACILLUS CALMETTE-GUERIN VERSUS MITOMYCIN C ALONE IN PATIENTS WITH SUPERFICIAL BLADDER CANCERJournal of Urology, VOL. 160, NO. 5, (1668-1672), Online publication date: 1-Nov-1998.Okamura T, Tozawa K, Yamada Y, Sakagami H, Ueda K and Kohri K (2018) Clinicopathological Evaluation of Repeated Courses of Intravesical Bacillus Calmette-Guerin Instillation for Preventing Recurrence of Initially Resistant Superficial Bladder CancerJournal of Urology, VOL. 156, NO. 3, (967-971), Online publication date: 1-Sep-1996.Rintala E, Jauhiainen K, Kaasinen E, Nurmi M and Alfthan O (2018) Alternating Mitomycin C and Bacillus Calmette-Guerin Instillation Prophylaxis For Recurrent Papillary (Stages Ta to T1) Superficial Bladder CancerJournal of Urology, VOL. 156, NO. 1, (56-60), Online publication date: 1-Jul-1996. Volume 154Issue 6December 1995Page: 2050-2053 Advertisement Copyright & Permissions© 1995 by American Urological Association, Inc.MetricsAuthor Information Erkki Rintala More articles by this author Kari Jauhiainen More articles by this author Pertti Rajala More articles by this author Mirja Ruutu More articles by this author Eero Kaasinen More articles by this author Olof Alfthan More articles by this author The Finnbladder Group More articles by this author Expand All Advertisement PDF downloadLoading ...